What Happens When GLP-1 Medications Are Stopped?

This page summarizes what is reported in the published literature. It is not medical advice. Decisions about continuing, tapering, or stopping any prescription medication should be made with the prescribing clinician.

Appetite changes

GLP-1 receptor agonists reduce appetite primarily through central satiety pathways and by slowing gastric emptying. When the medication is discontinued, these pharmacologic effects diminish over a period of weeks. Many patients report a return of pre-treatment hunger patterns, including increased frequency of hunger and reduced post-meal satiety.

Weight regain

Withdrawal cohorts from large GLP-1 trials have reported substantial weight regain over the year following discontinuation. For example, an extension of the STEP 1 trial reported that participants regained approximately two-thirds of their lost body weight within one year of stopping semaglutide and lifestyle support. Magnitude varies by individual, baseline characteristics, and the level of continued behavioral support.

Behavioral and environmental factors

Weight outcomes after discontinuation are also shaped by non-pharmacologic factors: nutritional patterns, physical activity, sleep, stress, food environment, and access to ongoing behavioral support. Patients who maintain structured nutrition and activity patterns after discontinuation may experience a different trajectory than those without this support, although population data still show meaningful regain on average.

Long-term planning

Patients and clinicians may consider several possibilities when planning beyond initial GLP-1 therapy. None is universally preferred:

• Continued maintenance therapy, with the lowest effective dose and ongoing monitoring.
• Cycling, tapering, or transitioning to alternative pharmacotherapy when clinically appropriate.
• Intensified behavioral and nutritional support during and after any taper.
• Evaluation for bariatric or metabolic procedures in eligible patients, which may offer a different durability profile.
• Combined pathways — for example, using GLP-1 therapy in the perioperative window or for weight regain after surgery (see Can GLP-1 Medications and Surgery Work Together?).

The most appropriate long-term plan is individualized. Clinicians typically weigh the severity of obesity, comorbid conditions, tolerability of medication, patient preferences, access and affordability, and prior treatment history.